Suppr超能文献

在两种亨廷顿舞蹈症小鼠模型中,脂肪组织功能障碍与疾病进展相关。

Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models.

作者信息

Phan Jack, Hickey Miriam A, Zhang Peixiang, Chesselet Marie-Francoise, Reue Karen

机构信息

Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095, USA.

出版信息

Hum Mol Genet. 2009 Mar 15;18(6):1006-16. doi: 10.1093/hmg/ddn428. Epub 2009 Jan 5.

Abstract

In addition to the hallmark neurological manifestations of Huntington's disease (HD), weight loss with metabolic dysfunction is often observed in the later stages of disease progression and is associated with poor prognosis. The mechanism for weight loss in HD is unknown. Using two mouse models of HD, the R6/2 transgenic and CAG140 knock-in mouse strains, we demonstrate that adipose tissue dysfunction is detectable at early ages and becomes more pronounced as the disease progresses. Adipocytes acquire a 'de-differentiated' phenotype characterized by impaired expression of fat storage genes. In addition, HD mice exhibit reduced levels of leptin and adiponectin, adipose tissue-derived hormones that regulate food intake and glucose metabolism. Importantly, some of these changes occur prior to weight loss and development of some of the characteristic neurological symptoms. We demonstrate that impaired gene expression and lipid accumulation in adipocytes can be recapitulated by expression of an inducible mutant huntingtin transgene in an adipocyte cell line and that mutant huntingtin inhibits transcriptional activity of the PGC-1alpha co-activator in adipocytes, which may contribute to aberrant gene expression. Thus, our findings indicate that mutant huntingtin has direct detrimental effects in cell types other than neurons. The results also indicate that circulating adipose-tissue-derived hormones may be accessible markers for HD prognosis and progression and suggest that adipose tissue may be a useful therapeutic target to improve standard of life for HD patients.

摘要

除了亨廷顿舞蹈症(HD)典型的神经学表现外,在疾病进展后期常观察到体重减轻及代谢功能障碍,且这与预后不良相关。HD患者体重减轻的机制尚不清楚。我们使用两种HD小鼠模型,即R6/2转基因小鼠和CAG140基因敲入小鼠品系,证明脂肪组织功能障碍在早期即可检测到,并随着疾病进展而愈发明显。脂肪细胞呈现出一种“去分化”表型,其特征为脂肪储存基因的表达受损。此外,HD小鼠体内瘦素和脂联素水平降低,这两种脂肪组织衍生的激素可调节食物摄入和葡萄糖代谢。重要的是,其中一些变化发生在体重减轻和一些典型神经症状出现之前。我们证明,在脂肪细胞系中表达可诱导的突变型亨廷顿蛋白转基因可重现脂肪细胞中基因表达受损和脂质积累的现象,且突变型亨廷顿蛋白会抑制脂肪细胞中PGC-1α共激活因子的转录活性,这可能导致异常基因表达。因此,我们的研究结果表明,突变型亨廷顿蛋白对神经元以外的细胞类型具有直接有害作用。研究结果还表明,循环中的脂肪组织衍生激素可能是HD预后和疾病进展的可检测标志物,并提示脂肪组织可能是改善HD患者生活质量的一个有用治疗靶点。

相似文献

1
Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models.
Hum Mol Genet. 2009 Mar 15;18(6):1006-16. doi: 10.1093/hmg/ddn428. Epub 2009 Jan 5.
2
Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
J Neurochem. 2013 May;125(3):410-9. doi: 10.1111/jnc.12190. Epub 2013 Mar 5.
3
Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
Mol Metab. 2022 Mar;57:101439. doi: 10.1016/j.molmet.2022.101439. Epub 2022 Jan 7.
5
The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
Biochim Biophys Acta. 2011 Sep;1812(9):1111-20. doi: 10.1016/j.bbadis.2011.05.006. Epub 2011 May 30.
6
Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease.
PLoS One. 2013;8(4):e59438. doi: 10.1371/journal.pone.0059438. Epub 2013 Apr 2.
7
Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
Hum Mol Genet. 2010 Oct 15;19(20):4043-58. doi: 10.1093/hmg/ddq322. Epub 2010 Jul 28.
10
Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
Neurobiol Dis. 2011 Jan;41(1):43-50. doi: 10.1016/j.nbd.2010.08.017. Epub 2010 Aug 22.

引用本文的文献

1
Silent destruction: hidden muscle wasting and body decline in early Huntington's disease.
J Neural Transm (Vienna). 2025 Jul 28. doi: 10.1007/s00702-025-02991-3.
2
Brain-Periphery Interactions in Huntington's Disease: Mediators and Lifestyle Interventions.
Int J Mol Sci. 2024 Apr 25;25(9):4696. doi: 10.3390/ijms25094696.
6
Metabolism in Huntington's disease: a major contributor to pathology.
Metab Brain Dis. 2022 Aug;37(6):1757-1771. doi: 10.1007/s11011-021-00844-y. Epub 2021 Oct 27.
7
Systemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis.
Ageing Res Rev. 2021 Aug;69:101358. doi: 10.1016/j.arr.2021.101358. Epub 2021 May 9.
8
Converging evidence in support of omega-3 polyunsaturated fatty acids as a potential therapy for Huntington's disease symptoms.
Rev Neurosci. 2021 Apr 5;32(8):871-886. doi: 10.1515/revneuro-2021-0013. Print 2021 Dec 20.
9
Longitudinal expression changes are weak correlates of disease progression in Huntington's disease.
Brain Commun. 2020 Oct 17;2(2):fcaa172. doi: 10.1093/braincomms/fcaa172. eCollection 2020.
10
Structural and functional features of medium spiny neurons in the BACHDΔN17 mouse model of Huntington's Disease.
PLoS One. 2020 Jun 23;15(6):e0234394. doi: 10.1371/journal.pone.0234394. eCollection 2020.

本文引用的文献

1
Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.
Neuroscience. 2008 Nov 11;157(1):280-95. doi: 10.1016/j.neuroscience.2008.08.041. Epub 2008 Aug 27.
2
Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10820-5. doi: 10.1073/pnas.0800658105. Epub 2008 Jul 31.
4
Adipose tissue hormones and the regulation of food intake.
J Neuroendocrinol. 2008 Jun;20(6):842-9. doi: 10.1111/j.1365-2826.2008.1730.x.
7
The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study.
Exp Neurol. 2008 Apr;210(2):691-8. doi: 10.1016/j.expneurol.2007.12.026. Epub 2008 Jan 19.
8
Adipokines and the peripheral and neural control of energy balance.
Mol Endocrinol. 2008 May;22(5):1023-31. doi: 10.1210/me.2007-0529. Epub 2008 Jan 17.
9
Obesity and lipodystrophy--where do the circles intersect?
Endocrinology. 2008 Mar;149(3):925-34. doi: 10.1210/en.2007-1355. Epub 2008 Jan 17.
10
The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Metabolism. 2008 Feb;57(2):268-73. doi: 10.1016/j.metabol.2007.09.011.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验